We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Results for 'CMO ADC'

Content Type: All
Sorted by: Relevance

Content Type
Sort by

Showing 1 to 10 results of 442


Piramal Aiming High in ADC Market

Company targets becoming the global market leader in development & manufacturing of ADCs.

Scottish CMO to Unveil Facility Expansion at CPhI

CMO will increase floor space at its Scotland-based site by 20%.

CRT and ADC Therapeutics Join Forces on ADCs

Both Companies sign agreements to develop ADCs using CRT antibodies and peptides, and ADCT’s ‘warhead’ and linker chemistries.

Novasep Invests €10M to Reinforce its Bioconjugation Services

Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.

Bruker Announces Acquisition of CMO InVivo Biotech

Bruker Announces Acquisition of CMO InVivo Biotech to Expand Molecular Biology, Microbiology and Pathology Consumables and Assay Business

ADC Therapeutics Drives Productivity with Labguru

ADC Therapeutics develops proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.

NBE Announces Validation of its SMAC-Technology for ADC Development

Successful validation of SMAC™-Technology at World ADC summit 2014 in Frankfurt, Germany.

Carbogen Amcis AG Makes Capital Investments in ADC

New ADC capabilities benefit oncology innovators.

ADC Therapeutics Licenses Proprietary Antibodies from Five Prime Therapeutics

Adds an additional proprietary ADC development program in oncology.

Seattle Genetics and Genmab Enter into New ADC Collaboration

New ADC program will target AXL expressed on multiple tumor types.